GLP-1 pancreatitis concerns justified

Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.

The findings, published in JAMA Internal Medicine, show that patients taking sitagliptin and exenatide had double the risk for hospital admission for acute pancreatitis compared with Type 2 diabetes patients not taking these drugs.

The study included 1269 patients admitted to hospital with acute pancreatitis and 1269 control patients closely matched for age, gender, diabetes complications, and enrollment patterns.

Sonal Singh (Johns Hopkins University, Baltimore, Maryland, USA) and colleagues report that patients who were hospitalized with acute pancreatitis were more likely than controls to have hypertriglyceridemia (12.9 vs 8.4%), alcohol use (3.2 vs 0.2%), gallstones (9.1 vs 1.3%), tobacco abuse (16.4 vs 5.5%), obesity (19.6 vs 9.8%), biliary and pancreatic cancer (2.8 vs 0.0%), and cystic fibrosis (0.8 vs 0%).

However, after controlling for these factors, as well as metformin use, GLP-1 therapy use within the previous 30 days was still associated with a 2.24-fold increase in the odds for hospital admission for acute pancreatitis. Patients who had used GLP-1 agents in the past 2 years (but had stopped treatment at least 30 days earlier) were 2.01 times more likely to be admitted than nonusers.

Since the launch of GLP-1-based therapies, there have been numerous reports of acute pancreatitis among patients, and rodent models have supported this association. However, the authors say that previous population studies have lacked sufficient statistical power and failed to adequately control for confounders.

In a related commentary, Belinda Gier and Peter Butler, from the University of California, Los Angeles, USA, say that the findings are a warning that the drugs still have unknown effects, particularly on the risk for pancreatic cancer.

"Now that Singh and colleagues have brought clarity to the increased risk of pancreatitis with GLP-1-based therapy, the time has come to move forward and address the wider implications of this finding," they write.

The commentators add the research provides "a timely reminder that, despite large numbers of underpowered studies claiming the contrary from marketing companies, little is yet known about long-term adverse effects of the GLP-1 class of drugs on the exocrine pancreas."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Kirsty Oswald

Written by

Kirsty Oswald

Kirsty has a B.Sc. in Human Sciences from University College London. After several years working as medical copywriter, she became a medical journalist and is now freelance. Kirsty also works part-time as an editor for a London-based charity. She is particularly interested in the social and cultural aspects of science.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oswald, Kirsty. (2018, August 23). GLP-1 pancreatitis concerns justified. News-Medical. Retrieved on July 17, 2019 from

  • MLA

    Oswald, Kirsty. "GLP-1 pancreatitis concerns justified". News-Medical. 17 July 2019. <>.

  • Chicago

    Oswald, Kirsty. "GLP-1 pancreatitis concerns justified". News-Medical. (accessed July 17, 2019).

  • Harvard

    Oswald, Kirsty. 2018. GLP-1 pancreatitis concerns justified. News-Medical, viewed 17 July 2019,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Living with advanced breast cancer